BeOne Medicines Co-Founder & Director Exercises Options and Sells $11.3M in ADS Under 10b5-1 Plan

Insider Transaction Summary

On September 28, 2026, Xiaodong Wang, Director and Chair of the Scientific Advisory Board of BeOne Medicines Ltd. ($ONC), executed a series of transactions involving the exercise of stock options and subsequent sale of underlying American Depositary Shares (ADSs).

• Option Exercise: Exercised options to acquire 403,364 Ordinary Shares (delivered as 31,028 ADSs, where 1 ADS = 13 Ordinary Shares) at an exercise price equivalent to $2.84 per ordinary share ($36.90 per ADS), with total exercise costs of approximately $1.14M.
• Open Market Dispositions: Sold all 31,028 ADSs on the same day in multiple tranches at weighted-average prices ranging from $356.97 to $367.23, for aggregate gross proceeds of approximately $11.32 million (blended average price of ~$364.79 per ADS).
• Trading Plan: Sales were executed automatically pursuant to a pre-established Rule 10b5-1 trading plan adopted on June 9, 2026.

Post-Transaction Holdings

Following the disposition of the newly acquired ADSs:

• Direct ADS Ownership: 0
• Direct Ordinary Share Ownership: 4,588,113 Ordinary Shares
• Indirect Ordinary Share Ownership: Over 4.97 million Ordinary Shares held via Wang Investment LLC, family trusts, and spouse.
• Remaining Derivative Holdings: 806,715 share options directly held.

Market Significance

The transaction is classified as Medium significance. While the total gross disposition exceeds $11.3 million, it represents a routine option exercise and sale conducted under a Rule 10b5-1 plan ahead of the option's November 15, 2026 expiration date. The reporting owner retains multi-million-share equity stakes directly and indirectly, indicating substantial ongoing alignment with the company.